Target density, not affinity or avidity of antigen recognition, determines adoptive t cell therapy outcomes in a mouse lymphoma model

Abstract

Adoptive T cell therapy (ACT) with antitumor CTL is a promising and tailored treatment against cancer.We investigated the role played by the affinity and avidity of the interaction between the tumor and the CTL on the outcome of ACT against a mouse non-Hodgkin B cell lymphoma that expresses OVA as a model neoantigen. ACT was assessed under conditions where antitumor CTL expressed TCR of varying affinity for OVA. We also assessed conditions where the avidity of Ag recognition varied because the lymphoma cells expressed high or low levels of OVA. Efficient eradication of small tumor burdens was achieved by high-or lowaffinity CTL. Tumors expressing low levels of OVA could also be eliminated. H..